Gisela Cáceres

1.2k total citations
27 papers, 787 citations indexed

About

Gisela Cáceres is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Gisela Cáceres has authored 27 papers receiving a total of 787 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Hematology and 8 papers in Genetics. Recurrent topics in Gisela Cáceres's work include Acute Myeloid Leukemia Research (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Gisela Cáceres is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Multiple Myeloma Research and Treatments (5 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Gisela Cáceres collaborates with scholars based in United States, Canada and Venezuela. Gisela Cáceres's co-authors include Shigeru Kakuta, Yoichiro Iwakura, Shinobu Saijo, Thiagarajan Venkataraman, Rachel Elsby, Glen N. Barber, Alan F. List, Lubomir Sokol, Justine Clark and Kathy L. McGraw and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Gisela Cáceres

27 papers receiving 771 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gisela Cáceres United States 15 360 350 195 118 105 27 787
Yaomei Wang China 12 316 0.9× 234 0.7× 116 0.6× 80 0.7× 143 1.4× 26 696
Laura Pattacini Italy 13 159 0.4× 247 0.7× 196 1.0× 87 0.7× 132 1.3× 26 624
J. Arnoud Marquart Netherlands 15 152 0.4× 204 0.6× 348 1.8× 38 0.3× 116 1.1× 25 843
Jörg Schüttrumpf Germany 14 205 0.6× 135 0.4× 166 0.9× 99 0.8× 86 0.8× 39 588
Tiffany Tate United States 10 295 0.8× 142 0.4× 151 0.8× 140 1.2× 86 0.8× 18 646
Yuji Yufu Japan 14 244 0.7× 238 0.7× 146 0.7× 379 3.2× 137 1.3× 36 872
Takeshi Otani Japan 15 316 0.9× 411 1.2× 58 0.3× 180 1.5× 45 0.4× 48 889
T Onuma Japan 4 206 0.6× 365 1.0× 217 1.1× 165 1.4× 51 0.5× 4 784
Paul Vink Netherlands 12 213 0.6× 726 2.1× 60 0.3× 172 1.5× 57 0.5× 15 1.1k
Frank J. Ward United Kingdom 15 148 0.4× 474 1.4× 103 0.5× 176 1.5× 34 0.3× 34 782

Countries citing papers authored by Gisela Cáceres

Since Specialization
Citations

This map shows the geographic impact of Gisela Cáceres's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gisela Cáceres with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gisela Cáceres more than expected).

Fields of papers citing papers by Gisela Cáceres

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gisela Cáceres. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gisela Cáceres. The network helps show where Gisela Cáceres may publish in the future.

Co-authorship network of co-authors of Gisela Cáceres

This figure shows the co-authorship network connecting the top 25 collaborators of Gisela Cáceres. A scholar is included among the top collaborators of Gisela Cáceres based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gisela Cáceres. Gisela Cáceres is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gupta, Shilpa, Jasreman Dhillon, Anthony Magliocco, et al.. (2019). Results from a phase I/Ib trial of enzalutamide and gemcitabine and cisplatin in metastatic bladder cancer (mBC).. Journal of Clinical Oncology. 37(7_suppl). 471–471. 12 indexed citations
2.
Cáceres, Gisela, John Puskas, & Anthony M. Magliocco. (2015). Circulating Tumor Cells: A Window into Tumor Development and Therapeutic Effectiveness. Cancer Control. 22(2). 167–176. 17 indexed citations
3.
McGraw, Kathy L., Ashley A. Basiorka, Joseph Johnson, et al.. (2014). Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors. PLoS ONE. 9(12). e114249–e114249. 21 indexed citations
4.
Wei, Sheng, X Chen, Kathy L. McGraw, et al.. (2012). Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 32(9). 1110–1120. 74 indexed citations
5.
Venner, Christopher P., Thomas J. Nevill, H. Joachim Deeg, et al.. (2012). Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome. Haematologica. 98(3). 409–413. 26 indexed citations
6.
Basiorka, Ashley A., Kathy L. McGraw, Ling Zhang, et al.. (2012). Lenalidomide Upregulates Erythropoietin Receptor Expression Through Inhibition of the E3-Ubiquitin Ligase Ring Finger Protein 41 (RNF41). Blood. 120(21). 3455–3455. 1 indexed citations
7.
Nof, Eyal, Héctor Barajas-Martínez, M. Eldar, et al.. (2011). LQT5 masquerading as LQT2: a dominant negative effect of KCNE1-D85N rare polymorphism on KCNH2 current. EP Europace. 13(10). 1478–1483. 20 indexed citations
8.
Sokol, Lubomir, Gisela Cáceres, Stefano Volinia, et al.. (2011). Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. British Journal of Haematology. 153(1). 24–32. 59 indexed citations
9.
Sokol, Lubomir, et al.. (2010). Monoclonal Gammopathy of Undetermined Significance Disguised as Chronic Neutrophilic Leukemia. Mediterranean Journal of Hematology and Infectious Diseases. 2(1). e2010002–e2010002. 3 indexed citations
10.
11.
Sugimori, Chiharu, Kenneth H. Shain, Gisela Cáceres, et al.. (2010). Co-existence of JAK V617F and PIG-A mutations in primary Budd-Chiari syndrome. 1. 1 indexed citations
12.
List, Alan F., Kathy Rocha, Ling Zhang, et al.. (2009). Secondary Resistance to Lenalidomide in Del(5q) MDS Is Associated with CDC25C & PP2A Overexpression.. Blood. 114(22). 292–292. 11 indexed citations
13.
Sokol, Lubomir, et al.. (2009). JAK2V617F mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. Leukemia Research. 34(6). 821–823. 17 indexed citations
14.
Venkataraman, Thiagarajan, Rachel Elsby, Shigeru Kakuta, et al.. (2007). Loss of DExD/H Box RNA Helicase LGP2 Manifests Disparate Antiviral Responses. The Journal of Immunology. 178(10). 6444–6455. 324 indexed citations
15.
Cáceres, Gisela, et al.. (2003). Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors. Anti-Cancer Drugs. 14(7). 569–574. 18 indexed citations
16.
Cáceres, Gisela, et al.. (2003). Imaging of luciferase and GFP‐transfected human tumours in nude mice. Luminescence. 18(4). 218–223. 31 indexed citations
17.
Cáceres, Gisela, Michael J. Dauphinée, Leslie E. Eisele, Robert MacColl, & Gerald J. Mizejewski. (2003). Anti-prostate cancer and anti-breast cancer activities of two peptides derived from alpha-fetoprotein.. PubMed. 22(5). 2817–20. 11 indexed citations
18.
Andreotti, Peter E., et al.. (2003). Luminescence Applications for Chemotherapeutic Drug Development. Recent results in cancer research. 161. 3–12. 6 indexed citations
19.
Fuentes, Alberto, et al.. (2001). Photosensitizing activity of thiocolchicoside: photochemical and in vitro phototoxicity studies.. PubMed. 56(1). 83–8. 5 indexed citations
20.
Cáceres, Gisela, et al.. (1990). Hypothalamic and telencephalic catecholamine content in the brain of the teleost fish, Pygocentrus notatus, during the annual reproductive cycle. General and Comparative Endocrinology. 80(2). 257–263. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yaomei Wang Breakdown of academic impact, for papers by Laura Pattacini Breakdown of academic impact, for papers by J. Arnoud Marquart Breakdown of academic impact, for papers by Jörg Schüttrumpf Breakdown of academic impact, for papers by Tiffany Tate Breakdown of academic impact, for papers by Yuji Yufu Breakdown of academic impact, for papers by Takeshi Otani Breakdown of academic impact, for papers by T Onuma Breakdown of academic impact, for papers by Paul Vink Breakdown of academic impact, for papers by Frank J. Ward
Rankless by CCL
2026